Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Foundation for Orthopaedics and Regenerative Medicine
Studies have shown that stem cell treatment is safe and efficacious for the treatment of Aging Frailty. This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (MSCs) for the treatment of Frailty. Patients with Frailty will receive a single intravenous infusion of MSCs. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Aging Frailty
Understanding and willingness to sign a written informed consent document
You may not be if
Active infection
Active cancer
Chronic multisystem organ failure
Pregnancy
Clinically significant abnormalities on pre-treatment laboratory evaluation
Medical condition that would (based on the opinion of the investigator) compromise patient's safety.